LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP-Reference-Cited by-同舟云学术

LONG-TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW-UP

Published:2017-06 Issue: Volume:35 Page:235-236
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Montillo M.¹,Byrd J.C.²,Hillmen P.³,O'Brien S.⁴,Barrientos J.C.⁵,Reddy N.M.⁶,Coutre S.⁷,Tam C.S.⁸,Mulligan S.P.⁹,Jaeger U.¹⁰,Barr P.M.¹¹,Furman R.R.¹²,Kipps T.J.¹³,Thornton P.¹⁴,Moreno C.¹⁵,Pagel J.M.¹⁶,Burger J.A.¹⁷,Jones J.²,Dai S.¹⁸,Vezan R.¹⁹,James D.F.¹⁹,Brown J.R.²⁰

Affiliation:

1. Department of Haematology & Oncology; Niguarda Cancer Center, Niguarda Hospital; Milan Italy

2. Division of Hematology, Department of Internal Medicine; The Ohio State University Comprehensive Cancer Center; Columbus USA

3. Department of Haematology; The Leeds Teaching Hospitals, St. James Institute of Oncology; Leeds UK

4. Chao Family Comprehensive Cancer Center; University of California Irvine; Orange USA

5. Division of Hematology and Medical Oncology; Department of Medicine, Hofstra Northwell School of Medicine; Hempstead USA

6. Hematology/Oncology; Vanderbilt-Ingram Cancer Center; Nashville USA

7. Division of Hematology, Stanford Cancer Center; Stanford University School of Medicine; Stanford USA

8. Department of Haematology, Peter MacCallum Cancer Centre and St. Vincent's Hospital; Melbourne Australia

9. Hematology; Royal North Shore Hospital, St. Leonards; Australia

10. Division of Hematology and Hemostaseology; Medical University of Vienna; Wien Austria

11. James P. Wilmot Cancer Center | Department of Medicine, Hematology/Oncology; University of Rochester Medical Center; Rochester USA

12. Division of Hematology and Medical Oncology, Weill Cornell Medical College; New York USA

13. Moores Cancer Center; University of California San Diego; La Jolla USA

14. Department of Haematology; Beaumont Hospital; Dublin Republic of Ireland

15. Hematology Department; Hospital de la Santa Creu Sant Pau; Barcelona Spain

16. Hematologic Malignancies Program; Swedish Cancer Institute; Seattle USA

17. Department of Leukemia; University of Texas MD Anderson Cancer Center; Houston USA

18. Biostatistics; Pharmacyclics LLC, an AbbVie Company; Sunnyvale USA

19. Clinical Research; Pharmacyclics LLC, an Abbvie Company; Sunnyvale USA

20. Division of Hematologic Malignancies; CLL Center, Dana-Farber Cancer Institute; Boston USA

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The safety of Bruton's tyrosine kinase inhibitors in B‐cell malignancies: A systematic review;European Journal of Haematology;2022-09-29

2. Incorporating acalabrutinib, a selective next‐generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies;British Journal of Haematology;2020-11-20

3. Patterns of use and safety of ibrutinib in real‐life practice;British Journal of Clinical Pharmacology;2020-07-05

4. Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review;Clinical Lymphoma Myeloma and Leukemia;2020-07

5. Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?;Current Oncology Reports;2018-11-27